2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 841

Low Nucleoside Triphosphate Pyrophosphohydrolase Activity Contributes to Pathologic Mineralization in Systemic Sclerosis
Abstract Number: 869

Low Numbers of CD16+ Monocytes Predict Shorter Time to Relapse in Polymyalgia Rheumatica
Abstract Number: 2833

Low Plasma Concentrations of Apolipoprotein M Correlate to Disease Activity and Endothelial Dysfunction in SLE
Abstract Number: 1874

Low Rate of Progression in Cases of Isolated Raynaud’s Phenomenon Screened By Nailfold Videocapillaroscopy and Antinuclear Antibody Status Supports Negative Predictive Value of These Tests
Abstract Number: 513

Low Serum 25-Hydroxyvitamin D Level Is Not Associated with Decreased Bone Mass or Bone Quality in Patients with Rheumatoid Arthritis
Abstract Number: 2796

Low Versus High Dose Glucocorticosteroid Used in Lupus Nephritis: Is There a Difference
Abstract Number: 13L

Low-Dose IL-2 Therapy in Refractory SLE: Results from Single Center Phase I/IIa Clinical Trial
Abstract Number: 2521

Lower Baseline 14-3-3η Levels Are Associated with Better Patient Reported Outcomes in Tocilizumab Treated Patients
Abstract Number: 1558

Lower Expression of a Novel Cytoplasmic Long Noncoding RNA NR_122076 Contributes to Proliferation, Migration and Invasion of Fibroblast-like Synoviocytes from Patients with Rheumatoid Arthritis
Abstract Number: 6

Lower Omega-3 Fatty Acid Biomarkers Are Associated with Inflammatory Arthritis in a Population Positive for Anti-Citrullinated Protein Antibodies
Abstract Number: 1538

Lower Ratings of Pain Intensity in Older Adults Lead to Underestimation of Disease Activity By Disease Activity Score 28-C-Reactive Protein (DAS28-CRP) in Patients with Rheumatoid Arthritis
Abstract Number: 3001

Lumbar CT-Guided Steroid Infiltration on the Refractory Low Back Pain. Study of 258 Procedures in the Same Center
Abstract Number: 2025

Lupus Education Advancement Project (LEAP): Rheumatology Fellows Serving As Educators Increased Knowledge and Efficiency in Lupus Recognition and Referral By Providers in Primary and Emergency Care
Abstract Number: 2866

Lupus HDL Induces Pro-Inflammatory Responses in Macrophages By Binding LOX1Rand Failing to Promote ATF3 Activity
Abstract Number: 1491

M-Ficolin and MAp44 As Potential Markers of Subclinical Cardiovascular Comorbidity; Cardiac Evaluation By Coronary Computer Tomography and Myocardial Deformation of Left Ventricle in Early Rheumatoid Arthritis Patients

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].